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Edited by Masayuki MiyasakaAbstract The collagen-binding motif (CBM) peptide, a cleav-
age product of osteopontin (OPN), stimulated intracellular cal-
cium increase in human neutrophils. CBM peptide-stimulated
calcium was inhibited by pertussis toxin (PTX), suggesting the
inﬂuence of PTX-sensitive G-proteins. In addition CBM peptide
stimulated the chemotactic migration of human neutrophils and
human monocytes. CBM peptide-induced neutrophil chemotaxis
was completely inhibited by PTX, once again indicating the
inﬂuence of Gi proteins. CBM peptide was also found to induce
mitogen activated protein kinase activation. CBM peptide-in-
duced neutrophil chemotaxis was mediated by p38 kinase as well
as an extracellular signal-regulated protein kinase. Taken to-
gether, the results suggest that a cleavage product of OPN,
CBM peptide, initiates immune responses by inducing neutrophil
traﬃcking via certain PTX-sensitive cell surface receptors.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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protein kinase1. Introduction
Neutrophils play important roles in innate immune re-
sponses [1]. The activities of neutrophils include migration into
an infected area and the generation of reactive oxygen species
such as the superoxide anion [1]. Until now, several extracellu-
lar stimuli including classical chemoattractants such as formyl-
methionyl-leucyl-phenylalanine (fMLF), complement compo-
nent C5a, and leukotriene B4 as well as several chemokines,
have been reported as being modulators of neutrophil activity
[2–5]. Previous reports have suggested that the stimulation of
neutrophils by extracellular stimuli induces cytoskeletal rear-
rangements, exocytosis, histamine release, receptor induction,
adhesion, the production of bioactive lipids, and the activationAbbreviations: OPN, osteopontin; CBM, collagen-binding motif; FBS,
fetal bovine serum; PTX, pertussis toxin; ERK, extracellular signal-
regulated protein kinase; MAPK, mitogen activated protein kinase;
[Ca2+]i, intracellular calcium concentration
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[2,3]. Because the chemotactic migration into an infected or
damaged site is important for the initiation of immune re-
sponses, the identiﬁcation of molecules that regulate neutro-
phil migration has received much attention.
Osteopontin (OPN) acts as a multifunctional cytokine that is
involved in diverse inﬂammatory diseases of the brain, liver,
gastrointestinal tract, bone, lung, and kidney [6,7]. Previous re-
ports demonstrated that an increase in OPN levels is associated
with increased cell migration [8,9]. In particular, OPN has been
known to regulate the cellular activities of macrophages and
ﬁbroblasts involved in the regulation of inﬂammatory diseases
[8,9]. Moreover, CD44 has been reported as the molecular tar-
get receptor for OPN [10]. Recently, Park and colleagues re-
ported that one of OPNs cleavage products, the collagen-
binding motif (CBM) peptide, was found to increase its cell
adhesion and growth [11]. The CBM peptide also increased
osteoblast diﬀerentiation, suggesting a potential role for the
induction of osteogenesis [11].
In this study, we investigated the inﬂuence of CBM peptide,
a cleavage product of OPN, on human neutrophil traﬃck-
ing. Furthermore, we investigated the signaling pathways
involved in the regulation of CBM peptide-induced neutrophil
chemotaxis.2. Materials and methods
2.1. Materials
The synthetic peptides, CBM peptide [residues 150–177 of human
OPN (GLRSKSKKFRRPDIQYPDATDEDITSHM)] [11] and
WKYMVm [12] were synthesized from Anygen Co. Ltd. (Gwang-ju,
Korea). The purity of all the synthetic peptide was >98%. Peripheral
blood mononuclear cell separation medium (Histopaque-1077) and
cytochrome c from Sigma (St. Louis, MO); fura-2 pentaacetoxymethy-
lester (fura-2/AM) from Molecular Probes (Eugene, OR); RPMI 1640
media and fetal bovine serum (FBS) were from Invitrogen Corp.
(Carlsbad, CA). Pertussis toxin (PTX), PD98059 and SB203580 were
purchased from Calbiochem (San Diego, CA). Enhanced chemilumi-
nescence reagents from Amersham Biosciences (Piscataway, NJ),
anti-phospho-extracellular signal-regulated protein kinase (ERK)1/2
and anti-phospho-p38 mitogen activated protein kinase (MAPK) anti-
bodies were purchased from New England Biolabs (Beverly, MA).
2.2. Isolation of human phagocytes
Peripheral blood was collected from healthy donors, and human
neutrophils were isolated by dextran sedimentation, hypotonic lysis
of erythrocytes, and by using a lymphocyte separation mediumblished by Elsevier B.V. All rights reserved.
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Fig. 1. The eﬀect of CBM peptide on intracellular calcium increases in
human neutrophils. Human neutrophils were stimulated with 400 lg/
ml of CBM peptide, 400 lg/ml of a scrambled peptide, or 1 lM of
WKYMVm (A). Human neutrophils were stimulated with several
concentrations of CBM peptide or 1 lM of WKYMVm (B). Human
neutrophils were cultured in the absence or presence of 100 ng/ml of
PTX for 24 h. Human neutrophils were stimulated with 400 lg/ml of
CBM peptide, 1 lM of WKYMVm, or 500 lM of ATP (C). [Ca2+]i
was determined ﬂuorometrically using fura-2/AM. The peak [Ca2+]i
levels were recorded and the results represented are from four
independent experiments (A and C). The data are presented as
means ± S.E. of three independent experiments performed in duplicate
(B).
3380 M.-K. Kim et al. / FEBS Letters 582 (2008) 3379–3384gradient as described previously [13]. Isolated neutrophils were main-
tained in RPMI 1640 medium supplemented 5% FBS at 37 C. Isolated
human neutrophils were used promptly. Peripheral blood mononu-
clear cells were separated on a Histopaque-1077 gradient. After two
washings with HBSS without Ca2+ and Mg2+, the peripheral blood
mononuclear cells were suspended in 10% FBS containing RPMI
and incubated for 60 min at 37 C to let the monocytes attach to the
culture dish. The cells were washed ﬁve times with warmed RPMI med-
ium to washout lymphocytes, and then the attached monocytes were
collected as described previously [14].
2.3. Measurement of intracellular calcium concentration
Intracellular calcium concentration ([Ca2+]i) was determined by Gry-
nkiewiczs method using fura-2/AM [15]. Brieﬂy, prepared cells were
incubated with 3 lM fura-2/AM at 37 C for 50 min in fresh serum free
RPMI 1640 medium with continuous stirring. Cells (2 · 106) were ali-
quoted for each assay into Lockes solution (154 mM NaCl, 5.6 mM
KCl, 1.2 mM MgCl2, 5 mM HEPES, pH 7.3, 10 mM glucose,
2.2 mM CaCl2, and 0.2 mM EGTA). Fluorescence was measured at
500 nm at excitation wavelengths of 340 nm and 380 nm.
2.4. Chemotaxis assay
Chemotaxis assays were performed using multiwell chambers (Neu-
roprobe Inc., Gaithersburg, MD) as previously described [15]. Brieﬂy,
prepared human neutrophils were suspended in RPMI at 1 · 106 cells/
ml, and 25 ll of this suspension was placed into the upper well of a
chamber separated by a 3 lm (5 lm for monocytes) polyhydrocarbon
ﬁlter from the peptide containing lower well. Migrated cells were
stained cells with hematoxylin and then counted in ﬁve randomly cho-
sen high power ﬁelds (400·) [15].
2.5. Measurement of superoxide generation
Superoxide anion generation was determined by measuring cyto-
chrome c reduction using a microtiter 96-well plate ELISA reader
(Bio-Tek instruments, EL312e, Winooski, VT) as previously described
[15]. Human neutrophils (2 · 106 cells in RPMI 1640 medium) were
preincubated with 50 lM of cytochrome c at 37 C for 1 min and then
incubated with each peptide. Superoxide generation was determined by
measuring light absorption changes at 550 nm over 5 min at 1 min
intervals.
2.6. Stimulation of neutrophils with CBM peptide for Western blot
analysis
Human neutrophils (2 · 106) were stimulated with CBM peptide
for several lengths of time (0, 2, 5, 10, and 30 min). After stimulation,
the cells were washed with serum free RPMI 1640 medium and lysed
in lysis buﬀer (20 mM HEPES, pH 7.2, 10% glycerol, 150 mM NaCl,
1% Triton X-100, 50 mM NaF, 1 mM Na3VO4, 10 lg/ml leupeptin,
10 lg/ml aprotinin, and 1 mM phenylmethylsulfonyl ﬂuoride).
Detergent insoluble materials were pelleted by centrifugation
(12000 · g, 15 min, at 4 C), and the soluble supernatant fraction
was removed and stored at either 80 C or used immediately. Protein
concentrations in lysates were determined using Bradford protein
assay reagent.
2.7. Electrophoresis and immunoblot analysis
Protein samples were prepared for electrophoresis and then sepa-
rated using a 10% SDS–polyacrylamide gel and the buﬀer system de-
scribed previously [15]. Following electrophoresis, they were blotted
onto nitrocellulose membrane, which were then blocked by incuba-
tion in TBST (Tris-buﬀered saline, 0.05% Tween-20) containing 5%
non-fat dried milk. The membranes were then incubated with anti-
phospho-ERK antibody, anti-phospho-p38 kinase antibody or anti-
ERK antibody and washed with TBST. Antigen–antibody complexes
were visualized using an enhanced chemiluminescence detection sys-
tem by incubating membranes with 1:5000 diluted goat anti-rabbit
IgG or goat anti-mouse IgG antibody coupled to horseradish perox-
idase.
2.8. Statistics
The results are expressed as means ± S.E. of the number of determi-
nations indicated. Statistical signiﬁcance of diﬀerences was determined
by Student t-test. Signiﬁcance was accepted when P < 0.05.3. Results
3.1. CBM peptide stimulates intracellular calcium increase in
human neutrophils
Previous study has demonstrated that the activation of G-
protein, coupled with receptor binding, causes diverse intracel-
lular signals, including [Ca2+]i increases [2]. To investigate
whether CBM peptide is functional in neutrophils, we exam-
ined the eﬀect of CBM peptide upon [Ca2+]i in neutrophils.
As shown in Fig. 1A, the stimulation of human neutrophils
with CBM peptide elicited an in crease in [Ca2+]i. CBM peptide
stimulated [Ca2+]i increase in a concentration-dependent man-
M.-K. Kim et al. / FEBS Letters 582 (2008) 3379–3384 3381ner, showing a maximal activity at 400 lg/ml of peptide
(Fig. 1B). A scrambled peptide (MHSTIDEDTADPY-
QIDPRRFKKSKSRLG) of CBM did not aﬀect on [Ca2+]i in-
crease in human neutrophils (Fig. 1A). We also examined the
eﬀect of PTX, a speciﬁc inhibitor of Gi/o type G proteins, on
CBM peptide-induced [Ca2+]i increase. When human neutro-
phils were preincubated with 100 ng/ml of PTX prior to being
stimulated with 400 lg/ml of CBM peptide, the CBM peptide-
induced [Ca2+]i increase was almost completely inhibited
(Fig. 1C). The results suggest the possibility that CBM peptide
stimulates an increase in [Ca2+]i via a PTX-sensitive pathway.
As a positive control, we also found that a WKYMVm-in-
duced [Ca2+]i increase was also completely inhibited by PTX
(Fig. 1C). In addition, we found that ATP also stimulated
[Ca2+]i increase in human neutrophils (Fig. 1C) and that the
ATP-stimulated [Ca2+]i increase was not aﬀected by PTX. This
suggests that ATP stimulated a [Ca2+]i increase in a PTX-
insensitive manner in human neutrophils.M
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Fig. 2. CBM peptide stimulates chemotactic migration but not
superoxide anion production in human neutrophils. Human neutro-
phils (1 · 106 cells/ml of serum free RPMI 1640 medium) were added
to the upper wells of a 96-well chemotaxis chamber and migration
across a 3 lm pore size polycarbonate membrane and assessed after
incubation at 37 C for 2 h. Various concentrations (0, 10, 100, 400,
and 800 lg/ml) of CBM peptide or a scrambled peptide, or 1 lM of
WKYMVm were used for the chemotaxis assay (A). Isolated human
neutrophils (2 · 106 cells/ml/assay) were preincubated for 1 min at
37 C with 50 lM of cytochrome c before being stimulated with
400 lg/ml of CBM peptide or 1 lM of WKYMVm for 5 min (B).
Cytochrome c reduction was monitored as a change in absorption at
550 nm at 1 min intervals over 5 min. The data are presented as
means ± S.E. of at least three independent experiments performed in
duplicate (A and B).3.2. CBM peptide induces chemotaxis of human neutrophils
We examined the inﬂuence of CBM peptide on the migration
of human neutrophils. Various concentrations of CBM peptide
(0, 10, 100, 400, and 800 lg/ml) caused neutrophil migration in
a concentration-dependant manner. We found that maximal
human neutrophil migration was observed with 400 lg/ml of
CBM peptide (Fig. 2A). The scrambled peptide of CBM did
not aﬀect on chemotactic migration in human neutrophils
(Fig. 2A). In proportion, the chemotactic migration of human
neutrophils by 400 lg/ml of CBM peptide was around 84% or
76% of the chemotactic migration of human neutrophils by
1 lM of fMLF or WKYMVm, two well-known neutrophil
chemoattractants [16,17]. To distinguish between CBM pep-
tide-induced chemotaxis and chemokinesis, we performed
migration assays in the absence or presence of CBM peptide
in the upper wells of the chambers, as described previously
[17]. The addition of CBM peptide (400 lg/ml) in the upper
chamber reduced the CBM peptide-induced migrations of neu-
trophils to the lower well (data not shown), which demon-
strates that CBM peptide induces neutrophil chemotaxis.
3.3. CBM peptide fails to stimulate superoxide generation in
human neutrophils
We examined the eﬀects of CBM peptide on superoxide gen-
eration by measuring cytochrome c reduction, as described
previously [18]. The stimulation of human neutrophils with
400 lg/ml of CBM peptide, in the presence of cytochalasin
B, did not induce superoxide generation (Fig. 2B). In addition,
CBM peptide also did not aﬀect superoxide generation in the
10–800 lg/ml concentration range (data not shown). As a po-
sitive control, WKYMVm was found to induce superoxide
generation in a time-dependent manner (Fig. 2B). To check
whether we failed to observe superoxide anion generation by
CBM peptide, since CBM peptide can scavenge the superoxide
anion, we examined its eﬀect on WKYMVm superoxide pro-
duction. The addition of CBM peptide did not aﬀect
WKYMVm-induced superoxide production (data not shown),
thus ruling out the possibility of CBM peptide as a scavenger
of superoxide anions.
3.4. CBM peptide induces chemotaxis of human monocytes
In addition to neutrophils, monocytes also play important
roles in immune responses. Therefore, we tested the eﬀect of
CBM peptide on the migration of human monocytes. CBM
peptide elicited chemotactic migration of human monocytes
in a concentration-dependant manner (Fig. 3). The chemotac-
tic migration of monocytes by 800 lg/ml of CBM peptide was
around 75% of what was observed by 1 lM WKYMVm, a
well-known monocyte chemoattractant [17]. The scrambled
peptide of CBM did not aﬀect on chemotactic migration in hu-
man monocytes (Fig. 3). We also examined the eﬀect of CBM
and WKYMVm on superoxide anion generation in human
monocytes. WKYMVm but not CBM stimulated superoxide
anion generation in human monocytes (data not shown).
3.5. CBM peptide induces neutrophil chemotaxis via PTX-
sensitive G-proteins
Many previous reports demonstrated that PTX-sensitive G-
protein-mediated signaling is critically involved in human neu-
trophil chemotaxis [2,19,20]. We also examined the eﬀect of
PTX on CBM peptide-induced neutrophil chemotaxis. When
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Fig. 3. CBM peptide stimulates chemotactic migration in human
monocytes. Human monocytes (1 · 106 cells/ml of serum free RPMI
1640 medium) were added to the upper wells of a 96-well chemotaxis
chamber and the migration across a 5 lm pore size polycarbonate
membrane was assessed after incubation at 37 C for 2 h. Various
concentrations (0, 10, 100, 400, and 800 lg/ml) of CBM peptide or a
scrambled peptide, or 1 lM of WKYMVm were used for the
chemotaxis assay. The data are presented as means ± S.E. of at least
three independent experiments performed in duplicate.
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Fig. 4. Regulation of CBM peptide-induced neutrophil chemotaxis.
Human neutrophils were preincubated with 100 ng/ml of PTX for 24 h
and a chemotaxis assay was performed using a vehicle, 400 lg/ml of
CBM peptide or 1 lM of WKYMVm (A). Neutrophils were stimu-
lated with 400 lg/ml of CBM peptide for various durations of time (0,
2, 5, 10, and 30 min). Thirty microgram aliquots of the cell lysates were
subjected to SDS–PAGE, followed by an immunoblot analysis using
anti-phospho-ERK antibodies or anti-phospho-p38 kinase antibodies
(B). A Western blot analysis was performed using anti-ERK antibody
to conﬁrm the sample loadings. The data shown are representative of
three independent experiments (B). The isolated human neutrophils
were treated with vehicle (DMSO), PD098059 (50 lM), or SB203580
(20 lM) for 15 min, and then subjected to chemotaxis assays in the
presence of CBM peptide at a concentration of 400 lg/ml for 1.5 h.
The number of migrated cells was determined by counting in ﬁve high
power ﬁelds (400·) (A and C). The data are presented as the
means ± S.E. of three independent experiments performed in duplicate
(A and C).
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prior to the chemotaxis assay, the number of cells migrating
toward CBM peptide was reduced by around 60% compared
to cells not treated with PTX (Fig. 4A). These results suggest
the involvement of PTX-sensitive G proteins in the CBM pep-
tide-induced chemotaxis of human neutrophils.
3.6. ERK activity is involved in the CBM peptide-induced
neutrophil chemotaxis
ERK has been reported to mediate extracellular signals to
the nucleus in a variety of cell types [21]. In this study, we at-
tempted to determine whether CBM peptide stimulates ERK
activity by Western blotting with anti-phospho-speciﬁc anti-
bodies of ERK. When human neutrophils were stimulated
with CBM peptide (400 lg/ml) for diﬀerent time durations,
ERK phosphorylation levels increased transiently, and exhib-
ited maximal activity after 2–5 min of stimulation and subse-
quently returned to baseline activity levels after 30 min of
stimulation (Fig. 4B). CBM peptide also stimulated p38 kinase
phosphorylation in a time-dependent manner, showing maxi-
mal activity at 2–5 min after stimulation (Fig. 4B). The scram-
bled peptide of CBM did not aﬀect on ERK and p38 kinase
activity in human neutrophils (data not shown).
We observed that CBM peptide dramatically induced hu-
man neutrophil chemotaxis (Fig. 2A). In order to elucidate
the intracellular pathways involved in the induction of neutro-
phil chemotaxis by CBM peptide, we assessed the chemotaxis
using the Boyden chamber assay in cells treated with an ERK
pathway inhibitor (PD98059), which prevents the activation of
MAPK kinase, an upstream activator of ERK1/2. PD98059
treatment was found to inhibit the CBM peptide-induced neu-
trophil chemotaxis (Fig. 4C), which suggests that the
PD98059-inhibitable MAPK pathway may be involved in the
CBM peptide-induced neutrophil chemotaxis. We also exam-
ined the eﬀects of the p38 kinase pathway on the CBM pep-
tide-induced neutrophil chemotaxis. As shown in Fig. 4C,
the pretreatment of human neutrophils with SB203580
M.-K. Kim et al. / FEBS Letters 582 (2008) 3379–3384 3383(20 lM) for 15 min prior to treating with CBM peptide, also
inhibited the chemotactic migration by CBM peptide. These
results suggest that not only ERK but also p38 kinase exert
a strong positive eﬀect on CBM peptide-induced human neu-
trophil migration.4. Discussion
In this study, we investigated the eﬀects of CBM peptide, the
cleavage product of OPN, on neutrophil chemotaxis. CBM
peptide inﬂuences the chemotactic migration of human neutro-
phils, suggesting that CBM peptide acts as a chemoattractant
for human neutrophils (Fig. 2A).
Neutrophils play a key role in the initiation of immune re-
sponses. In particular, neutrophil chemotactic migration is a
very important step for the induction of immune responses
against invading pathogens and other inﬂammatory environ-
ments [5,22]. Various kinds of soluble factors including
chemokines, induce neutrophil migration into infected or in-
jured regions of the body [5,22,23]. Recently, several reports
demonstrated that some peptide molecules, which are
released from the cleavage of intact cellular or extracellular
matrix proteins, act as new types of cytokines [24–26]. For in-
stance, acetylated Pro–Gly–Pro is released from collagen
degradation [24]. Acetylated Pro–Gly–Pro acts as a chemoat-
tractant for neutrophils and monocytes [24]. F2L (Ac-
MLGMIKNSLFGSVETWPWQVL), a peptide derived from
heme binding protein, also acts as a chemoattractant for
phagocytic cells [25,26]. In this study, we demonstrated that
CBM peptide, a peptide derived from OPN, stimulates neu-
trophil chemotaxis (Fig. 2A). Because CBM peptide was
identiﬁed from the enzymatic digestion of OPN with chymo-
trypsin [11], our results suggest that the generation of CBM
peptide induces the recruitment of inﬂammatory cells such
as neutrophils and monocytes where certain pathologic con-
ditions exist. This ﬁnding suggests a new role for the OPN
cleavage product (CBM peptide) as a modulator of inﬂamma-
tory responses.
Regarding the downstream signaling of CBM peptide-in-
duced neutrophil chemotaxis, we found that CBM peptide
stimulated the chemotactic migration of human neutrophils
in a PTX-sensitive manner (Fig. 4A). In addition, [Ca2+]i in-
creases induced by CBM peptide were also dramatically
inhibited by PTX (Fig. 1B). In summary, it is reasonable
to assume that CBM peptide can bind certain surface recep-
tors, which are coupled to PTX-sensitive G-proteins.
According to previous reports, OPN binds to certain cell
surface receptors, including CD44 and integrins [10,27,28].
Since CD44 and integrins are not coupled to PTX-sensitive
G-proteins, the results suggest that a cleavage product of
OPN (CBM peptide) can bind a diﬀerent target cell surface
than OPN.
The signal pathway of neutrophil chemotaxis by CBM pep-
tide was also investigated. At ﬁrst, we found that CBM peptide
stimulates two of the important kinases involved in MAPK
activity (ERK and p38 kinase) (Fig. 4B). The role ERK or
p38 kinase in CBM peptide-induced neutrophil chemotaxis
was tested using two diﬀerent MAPK-speciﬁc inhibitors
(PD98059 and SB203580), which are speciﬁc ERK and p38 ki-
nase inhibitors, respectively.The preincubation of neutrophils with PD98059 prior to a
chemotaxis assay using CBM peptide, dramatically inhibited
neutrophil chemotaxis by CBM peptide (Fig. 4C). Moreover,
SB203580 was also found to inhibit CBM peptide-induced
neutrophil chemotaxis (Fig. 4C). This indicates that both
ERK and p38 kinase play key roles in CBM peptide-induced
neutrophil chemotaxis.
In this study, we found that WKYMVm strongly stimulated
superoxide generation, but CBM peptide did not aﬀect super-
oxide generation in human neutrophils (Fig. 2B). Previously it
has been reported that for the proper activation of NADPH
oxidase, the activations of several factors, including cytosolic
phospholipase A2, phospholipase D, and Rac2 are essentially
required [29–31]. On the diﬀerential eﬀect of CBM and
WKYMVm on the generation of superoxide anion, it will be
possible that CBM may fail to stimulate signaling molecules
which are essentially required for the activation of NADPH
oxidase in human neutrophils.
In conclusion, our ﬁnding is that the cleavage products of
OPN, CBM peptide, can induce chemotactic migration in hu-
man neutrophils. Our ﬁndings provide a new perspective on
the roles of CBM peptide and its unknown receptor in the reg-
ulation of immune responses, via its chemotactic activity
involving human neutrophils.
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